Description:

ChromogenixCoatest®APC™Resistance–VSisanAPTT-basedassaykitforthescreeningoffactor-V-relatedAPCresistance.ThehighsensitivityandspecificityofthetestforthefactorV:Q506mutationisobtainedbypredilutingthesampleplasmawithanexcessofV-DEFPlasmabioreagent.ThetestdesignmakesitpossIBLetodiscriminatebetweenheterozygousandhomozygousfactorVgenotypes.Italsoallowsforanalysisofplasmafrompatientsonheparinororalanticoagulanttherapy.Highdiscriminationbetweengenotypeswith100%sensitivityforFV:Q506.ReducesneedforPCRdetermination.Applicabletoanticoagulanttreatedpatients.

Atime-andmoney-savingalternativetoindividualgenetictesting,Coatest©APC™Resistancetestingisanidealsolutionforphysiciansandlabs.Eachkitwasdesignedtobeeasytouseforin-housescreening,offeringfastresultsandlowcostsforbothlarge-andsmall-volumelabs.ThemostcommonFVLeidenscreeningtestperformed,itoffersunmatchedsensitivityfortheFV:Q506mutation–closeto100%specificity–andisapplicabletopatientsonheparinorwarfarin.

MeasurementPrinciple:

OnevolumeofplasmaispredilutedwithfourvolumesofV-DEFPlasma.ThedilutionisthenincubatedwiththeAPTTreagentforastandardperiodoftime.CoagulationistriggeredbytheadditionofCaCl2intheabsenceandpresenceofexogenousAPCandthetimeforclotformationisrecorded.

ActivatedProteinC(APC)isaregulatorofthecoagulationcascade,byspecificallyinactivatingfactorsVaandVIIIa,inthepresenceofphospholipidsandcalcium. Inmostofthecases(morethan90%),ActivatedProteinCResistance(APCR)phenotypeiscausedbyaFactorVgenemutation(FactorVLeiden).Themutation,locatedonFactorVexon10(1691G–>A),ofargininetoglutamineonposition506,rendersFactorVaresistanttothecleavagebyActivatedProteinC.ThisgeneticanomalycanbeevidencedwithaclottingmethodperformedinthepresenceortheabsenceofActivatedProteinC.

KitComposition:

ReagentsandStABIlity:

1.V-DEFPlasma2vialsStabilized,lyophilizedhumanplasma,withalowleveloffactorVactivity,containingtheheparinantagoNISTPolybrene®.Reconstitutewith4.0mLofNCCLStypeIIwater.Allowtostandfor30minutesat20-25°C.Swirlgentlybeforeuse.

2.CaCl22vials2mLofcalciumchloride,0.025mol/L,inTrisbuffercontaining0.5%bovineserumalbumin.

3. APTTreagent2vials4mLofpurifiedphospholipidswithcolloidalsilicaascontactactivator.Containsapreservative.MixthoroughlyonaVortexmixerbeforeuse.

4.APC/CaCl22vialsHumanactivatedproteinCcolyophilizedwithCaCl2.Reconstitutewith2.0mLofNCCLStypeIIwater.Allowtostandfor30minutesat20-25°C.Swirlgentlybeforeuse.

5.ControlPlasmaLevel1.1vialLyophilizedhumanplasma.Reconstitutewith1.0mLofNCCLStypeIIwater.Allowtostandfor30minutesat20-25°C.Swirlgentlybeforeuse.

6.ControlPlasmaLevel2.1vialLyophilizedhumanplasma.Reconstitutewith1.0mLofNCCLStypeIIwater.Allowtostandfor30minutesat20-25°C.Swirlgentlybeforeuse.

TestingAlgorithm:

IDEALFOR:

• Labslookingtobringtestingin-house
• Labslookingforcostsavings
• Orderingphysicianslookingforasensitiveassaywithrapidturnaround
• Savesthelabfromhavingtoperformgenetictestonallpatients
• Economicalalternativetogenetictesting

Background:

ActivatedProteinC(APC)isaregulatorofthecoagulationcascade,byspecificallyinactivatingfactorsVaandVIIIa,inthepresenceofphospholipidsandcalcium.

Inmostofthecases(morethan90%),ActivatedProteinCResistance(APCR)phenotypeiscausedbyaFactorVgenemutation(FactorVLeiden).Themutation,locatedonFactorVexon10(1691G–>A),ofargininetoglutamineonposition506,rendersFactorVaresistanttothecleavagebyActivatedProteinC.ThisgeneticanomalycanbeevidencedwithaclottingmethodperformedinthepresenceortheabsenceofActivatedProteinC.

ActivatedProteinCResistanceistestedbyusingaclottingmethodperformedwithorwithoutActivatedProteinC.

Readmore…